EMVERM Drug Patent Profile

Which patents cover Emverm, and when can generic versions of Emverm launch?

Emverm is a drug marketed by Impax Labs Inc and is included in one NDA.

The generic ingredient in EMVERM is mebendazole. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mebendazole profile page.

Summary for EMVERM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	142
Drug Prices:	Drug price information for EMVERM
DailyMed Link:	EMVERM at DailyMed

See drug prices for EMVERM

US Patents and Regulatory Information for EMVERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax Labs Inc	EMVERM	mebendazole	TABLET, CHEWABLE;ORAL	073580-001	Jan 4, 1995		RX	No	Yes

Emverm (Mebendazole) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Emverm (mebendazole) is an anthelmintic drug used to treat a variety of parasitic worm infections. Its market performance is influenced by its efficacy, cost-effectiveness, and the prevalence of parasitic diseases globally. This analysis examines Emverm's current market position and projected financial trajectory based on available patent data, regulatory approvals, and market trends.

What is the current patent landscape for Emverm?

The primary patent covering mebendazole, the active pharmaceutical ingredient in Emverm, expired decades ago. However, secondary patents related to specific formulations, manufacturing processes, or new indications can still be relevant.

• Original Composition of Matter Patent: The foundational patent for mebendazole has long expired. This has allowed for the development of generic versions of the drug.
• Formulation Patents: Patents covering specific formulations, such as chewable tablets, oral suspensions, or extended-release formulations, can extend market exclusivity for branded versions or offer differentiation for generic manufacturers. For example, patent US5700478A, filed in 1996 and expiring in 2017, covered a sustained-release formulation of mebendazole.
• Manufacturing Process Patents: Innovations in the synthesis or purification of mebendazole may be protected by patents. These patents can provide a competitive advantage by improving yield, reducing costs, or enhancing purity.
• New Indication Patents: Research into novel uses for mebendazole, such as its potential anti-cancer properties, has led to new patent applications and grants. For instance, patents related to mebendazole's use in treating certain types of cancer are active and represent future market opportunities.
• Exclusivity Periods: Regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity or Orphan Drug Exclusivity (ODE), can provide market protection independent of patent status. For mebendazole, these are less relevant for its traditional anthelmintic use due to its long history but can apply to new indications.

What is Emverm's approved therapeutic area and market positioning?

Emverm is primarily approved for the treatment of intestinal worm infections caused by common nematodes. Its positioning is that of a broad-spectrum, cost-effective treatment.

• Approved Indications: Emverm is indicated for the treatment of single or mixed whipworm (Trichuris trichiura) infections, roundworm (Ascaris lumbricoides) infections, and hookworm (Ancylostoma duodenale and Necator americanus) infections. It is also used for pinworm (Enterobius vermicularis) infections.
• Market Segmentation: The drug competes in the anthelmintic market, which is broadly segmented into human and veterinary applications. Within human health, it addresses a significant portion of the global burden of neglected tropical diseases (NTDs).
• Competitive Landscape: Emverm faces competition from other broad-spectrum anthelmintics such as albendazole, pyrantel pamoate, and praziquantel. Generic mebendazole is widely available and significantly impacts the pricing and market share of branded formulations.
• Branded vs. Generic: While branded Emverm may target specific markets or patient populations, the majority of mebendazole sales are through generic channels due to patent expiries. This creates a price-sensitive market.
• Key Differentiators: Branded Emverm may differentiate through specific formulations (e.g., improved palatability for pediatric use), targeted marketing, or availability in specific geographic regions where branded generics are preferred.

What is the global prevalence of parasitic worm infections impacting Emverm's market?

The global prevalence of parasitic worm infections, particularly in low- and middle-income countries, forms the primary demand driver for Emverm and similar anthelmintics.

• Neglected Tropical Diseases (NTDs): Many of the infections treated by Emverm are classified as NTDs by the World Health Organization (WHO). These diseases disproportionately affect impoverished communities.
• Estimated Global Burden:
  • Ascariasis: Affects an estimated 760 million people worldwide, with the highest prevalence in East Asia and sub-Saharan Africa [1].
  • Trichuriasis: Affects an estimated 575 million people globally, primarily in regions with poor sanitation and hygiene [1].
  • Hookworm: Affects an estimated 540 million people globally, concentrated in sub-Saharan Africa, Asia, and Latin America [1].
  • Pinworm: While less commonly a public health crisis, pinworm infections are highly prevalent globally, especially in childcare settings and households, affecting millions annually.
• Risk Factors: Poor sanitation, inadequate access to clean water, close living conditions, and a lack of public health education contribute to the high prevalence of these infections.
• Impact of Public Health Programs: Mass drug administration (MDA) programs, often supported by organizations like the WHO and pharmaceutical donations, are crucial in controlling these infections. Mebendazole is a key drug used in these programs due to its efficacy and safety profile.
• Regional Hotspots: Sub-Saharan Africa, Southeast Asia, and parts of Latin America are key regions with high endemicity for soil-transmitted helminths (STHs) – the primary target of Emverm's anthelmintic action.

What are Emverm's sales and revenue trends?

Analyzing specific sales figures for branded Emverm is challenging due to the prevalence of generic mebendazole. However, the overall mebendazole market and potential future revenue streams can be estimated.

• Generic Market Dominance: The global market for mebendazole is largely driven by generic sales, which are characterized by lower per-unit prices but higher volumes.
• Estimated Market Size (Mebendazole API): The global market for mebendazole Active Pharmaceutical Ingredient (API) is estimated to be in the tens of millions of U.S. dollars annually. This figure is difficult to precisely quantify due to fragmented manufacturing and diverse sales channels.
• Branded Emverm Sales: Specific revenue figures for branded Emverm are not publicly disclosed by its manufacturers (e.g., Nordic Group, which markets Emverm in specific regions). Its sales are likely to be a small fraction of the total mebendazole market, potentially in the low single-digit millions globally, depending on its geographic reach and specific marketing efforts.
• Projected Growth Drivers:
  • Continued MDA Programs: Ongoing and expanding WHO-supported MDA programs for STHs will sustain demand for mebendazole.
  • Emerging Markets: Increased healthcare access and public health initiatives in developing economies are expected to drive demand.
  • New Indications: Successful development and approval of mebendazole for non-anthelmintic indications (e.g., cancer) could significantly boost revenue and market value.
• Challenges to Revenue Growth:
  • Price Erosion: Intense competition from generic manufacturers limits price increases.
  • Commoditization: Mebendazole's status as an older, widely available drug makes it a commodity in many markets.
  • Competition: Availability of other effective anthelmintics.

What are the future market opportunities and R&D outlook for Emverm?

The future of Emverm is bifurcated: continued stable demand for its traditional use and significant potential from novel indications.

• Expanding Anthelmintic Use:
  • Increased Global Health Focus: Continued emphasis on eradicating neglected tropical diseases could lead to increased procurement and distribution of mebendazole.
  • Improved Formulations: Development of more palatable or easier-to-administer formulations, particularly for pediatric populations, could enhance market penetration.
  • Combination Therapies: Research into combining mebendazole with other anthelmintics for broader spectrum coverage or to combat resistance.
• Novel Therapeutic Areas (Oncology):
  • Mechanism of Action: Mebendazole has demonstrated anti-proliferative, anti-angiogenic, and anti-metastatic properties in preclinical and early clinical studies. It targets tubulin polymerization, essential for cell division, and has been shown to inhibit angiogenesis and induce apoptosis in cancer cells.
  • Targeted Cancers: Research is ongoing for its use in glioblastoma, non-small cell lung cancer, colon cancer, and other solid tumors.
  • Clinical Trials: Several Phase I and Phase II clinical trials are investigating mebendazole, often in combination with standard chemotherapy or other targeted agents. For example, trials are exploring its efficacy against recurrent glioblastoma [2].
  • Regulatory Hurdles: Translating these promising preclinical and early-stage clinical findings into approved indications requires extensive, multi-phase clinical trials, significant investment, and a lengthy regulatory review process.
  • Market Potential in Oncology: If successful, a mebendazole-based oncology drug could command significantly higher pricing and create substantial revenue streams, far exceeding its current anthelmintic market value. This represents the most significant growth opportunity.
• Repurposing and Combination Products:
  • Combination with Chemotherapy: Exploring synergistic effects with existing cancer therapies.
  • Drug Delivery Systems: Developing novel delivery systems to enhance bioavailability and target tumor sites.
• Challenges:
  • Drug Resistance: While less of a concern for STHs in terms of widespread clinical resistance, it is a potential factor for future anthelmintic use. For oncology, off-target effects and potential resistance mechanisms need careful study.
  • Clinical Trial Success Rate: The high failure rate in oncology drug development poses a significant risk.
  • Competition in Oncology: The oncology market is highly competitive, with many novel therapies under development.

Key Takeaways

• The traditional market for Emverm (mebendazole) as an anthelmintic is mature and largely dominated by generic competition, leading to price sensitivity.
• Global demand for mebendazole is sustained by ongoing mass drug administration programs targeting neglected tropical diseases in low- and middle-income countries.
• The most significant future market opportunity for mebendazole lies in its potential repurposing for oncology indications, supported by early-stage clinical research.
• Successful development and regulatory approval for cancer treatment would represent a paradigm shift in mebendazole's financial trajectory, enabling premium pricing and substantial revenue growth.
• The patent landscape for mebendazole itself has expired, but secondary patents on formulations and new indications, coupled with regulatory exclusivities for novel uses, will be crucial for future market protection.

Frequently Asked Questions

1. What is the primary mechanism of action for Emverm in treating parasitic worm infections? Emverm (mebendazole) works by inhibiting the formation of microtubules in the intestinal cells of parasitic worms. This disruption prevents the worms from absorbing glucose and other essential nutrients, leading to their immobilization and death.

2. How does Emverm's efficacy compare to other common anthelmintics like albendazole? Mebendazole and albendazole are both broad-spectrum anthelmintics with similar efficacy against common soil-transmitted helminths. They are often used interchangeably, with the choice sometimes depending on local availability, cost, and specific parasite species prevalent in a region.

3. What are the main hurdles for mebendazole to gain approval as an anti-cancer drug? The primary hurdles are demonstrating robust clinical efficacy in large-scale Phase III trials across specific cancer types, establishing a favorable safety profile compared to existing oncology treatments, and navigating the rigorous regulatory review process by agencies like the FDA and EMA.

4. Are there any known drug-drug interactions with Emverm that are critical for healthcare professionals to consider? Yes, mebendazole can interact with carbamazepine and phenytoin, potentially increasing their plasma concentrations. It can also interact with piperazine, which can reduce the efficacy of both drugs. Healthcare providers must review a patient's medication list before prescribing mebendazole.

5. What is the projected timeline for mebendazole to potentially become an approved cancer therapy? Given that mebendazole is still in early to mid-stage clinical trials for oncology indications, and considering the typical duration of Phase III trials and regulatory review, it could take anywhere from five to ten years or longer for potential approval, contingent on positive trial outcomes.

Citations

[1] World Health Organization. (2023). Soil-transmitted helminths. Retrieved from https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminths [2] ClinicalTrials.gov. (n.d.). Mebendazole for the Treatment of Recurrent Glioblastoma. Identifier NCT01897026. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01897026